登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
ClinicalTrials.gov 上登记的一项肺癌开放试验,由南昌大学第二附属医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07398599,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 99 岁;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC), staged as IV according to the 8th edition of the IASLC TNM classification (2015).
入选标准第 2 条
At least 21 days since the last radiotherapy (including whole-brain radiotherapy or local radiotherapy for brain metastases).
入选标准第 7 条
For women: Agreement to use effective contraception (e.g., surgical sterilization or protocol contraception) within 14 days prior to enrollment, during the study, and for 3 months after the last study drug administration.
入选标准第 10 条
For men: Agreement to use effective contraception (e.g., surgical sterilization or protocol contraception) during the study and for 3 months after the last study drug administration.
入选标准第 11 条
Major surgery within 4 weeks prior to the start of study treatment, or need for major surgery during the study.
排除标准第 1 条
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
入选标准第 5 条
Presence of EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R mutation).
入选标准第 3 条
Human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
排除标准第 2 条
History of other systemic malignant tumors within the past 5 years (except for cured basal cell carcinoma, carcinoma in situ of the cervix, and ovarian cancer).
排除标准第 7 条
Pregnancy, lactation, or refusal of effective contraception by patients of childbearing potential.
排除标准第 10 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07398599,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Aged ≥ 18 years at the time of signing the informed consent form, regardless of gender. Histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC), staged as IV according to the 8th edition of the IASLC TNM classification (2015). Presence of EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R mutation). Leptomeningeal metastasis (LM) progression after standard-dose first-, second-, or third-generation EGFR-TKI treatment. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. Adequate major organ function, defined as: hemoglobin (Hb) ≥ 90 g/L, absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L, platelet count (PLT) ≥ 100 × 10\^9/L, white blood cell count (WBC) ≥ 3.0 × 10\^9/L and ≤ 10.0 × 10\^9/L; total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN), alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5 × ULN; creatinine clearance ≥ 50 ml/min (for patients with liver metastases, TBIL ≤ 3.0 × ULN, ALT and AST ≤ 5.0 × ULN); activated partial thromboplastin time (APTT), international normalized ratio (INR), and prothrombin time (PT) ≤ 1.5 × ULN. At least 21 days since the last radiotherapy (including whole-brain radiotherapy or local radiotherapy for brain metastases). Expected survival ≥ 3 months. Ability to swallow oral medications (or receive crushed medications via gastrostomy tube if unable to swallow). For women: Agreement to use effective contraception (e.g., surgical sterilization or protocol contraception) within 14 days prior to enrollment, during the study, and for 3 months after the last study drug administration. For men: Agreement to use effective contraception (e.g., surgical sterilization or protocol contraception) during the study and for 3 months after the last study drug administration. Voluntary participation, signed informed consent, and willingness to comply with study procedures and protocols.排除标准:Exclusion Criteria:
Major surgery within 4 weeks prior to the start of study treatment, or need for major surgery during the study. Human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS). Active bacterial/fungal/viral infections requiring intravenous antibiotic therapy. Drug-induced pneumonitis or interstitial lung disease, or evidence of clinically significant active pulmonary disease. Severe cardiovascular events within 6 months prior to enrollment, including cerebrovascular accident, deep vein thrombosis, or pulmonary embolism. Significant cardiovascular disease, such as New York Heart Association (NYHA) class II or higher congestive heart failure, unstable angina, symptomatic arrhythmias requiring treatment, or corrected QT interval (QTcF) > 470 ms on consecutive electrocardiograms. History of other systemic malignant tumors within the past 5 years (except for cured basal cell carcinoma, carcinoma in situ of the cervix, and ovarian cancer). Use of drugs or supplements known to be strong inducers of CYP3A4. Known severe allergy to any study drug or its excipients. Pregnancy, lactation, or refusal of effective contraception by patients of childbearing potential. History of definite neurological or psychiatric disorders (including epilepsy and dementia). Other conditions deemed unsuitable for enrollment by the investigator.
引自 ClinicalTrials.gov, NCT07398599, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07398599,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。